

Richard L Wasserman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4046317/publications.pdf>

Version: 2024-02-01

91
papers

2,359
citations

236925

25
h-index

214800

47
g-index

99
all docs

99
docs citations

99
times ranked

2429
citing authors

#	ARTICLE	IF	CITATIONS
1	Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 729.	7.4	586
2	Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2010, 30, 734-745.	3.8	125
3	Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 951-957.e11.	2.9	113
4	Real-World Experience with Peanut Oral Immunotherapy: Lessons Learned From 270 Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 418-426.e4.	3.8	103
5	Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 91-96.e2.	3.8	91
6	Use of Genetic Testing for Primary Immunodeficiency Patients. <i>Journal of Clinical Immunology</i> , 2018, 38, 320-329.	3.8	88
7	Safety and Efficacy of Privigen [®] , a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2009, 29, 137-144.	3.8	87
8	PHYLOGENETICALLY ASSOCIATED RESIDUES WITHIN THE VHIII SUBGROUP OF SEVERAL MAMMALIAN SPECIES. <i>Journal of Experimental Medicine</i> , 1973, 138, 410-427.	8.5	73
9	Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD) Tj ETQq1 1 0.784314 rgBT /Overview of Clinical Immunology, 2011, 31, 323-331.	3.8	72
10	Caustic substance injuries. <i>Journal of Pediatrics</i> , 1985, 107, 169-174.	1.8	71
11	Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again. <i>Journal of Clinical Immunology</i> , 2012, 32, 1153-1164.	3.8	67
12	Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. <i>Immunotherapy</i> , 2014, 6, 553-567.	2.0	56
13	Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 157-163.	2.0	51
14	Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2012, 32, 663-669.	3.8	48
15	Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. <i>Immunotherapy</i> , 2017, 9, 1035-1050.	2.0	44
16	An Approach to the Office-Based Practice of Food Oral Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1826-1838.e8.	3.8	44
17	In vitro digestion of soluble cashew proteins and characterization of surviving <sc>I</sc>g<sc>E</sc> reactive peptides. <i>Molecular Nutrition and Food Research</i> , 2014, 58, 884-893.	3.3	37
18	Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 571-582.	3.8	37

#	ARTICLE	IF	CITATIONS
19	Heat-induced alterations in cashew allergen solubility and IgE binding. <i>Toxicology Reports</i> , 2016, 3, 244-251.	3.3	32
20	Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks. <i>Advances in Therapy</i> , 2012, 29, 913-922.	2.9	31
21	Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. <i>Immunotherapy</i> , 2016, 8, 1175-1186.	2.0	30
22	Oral immunotherapy for food allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 272-275.	1.0	30
23	Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. <i>Clinical Immunology</i> , 2014, 150, 161-169.	3.2	29
24	Decreased Immunoglobulin E (IgE) Binding to Cashew Allergens following Sodium Sulfite Treatment and Heating. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 6746-6755.	5.2	28
25	Personalized Therapy. <i>Immunology and Allergy Clinics of North America</i> , 2019, 39, 95-111.	1.9	28
26	C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 427-431.	2.2	23
27	Efficacy, Safety, and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease. <i>Journal of Clinical Immunology</i> , 2016, 36, 590-599.	3.8	22
28	Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. <i>Journal of Clinical Immunology</i> , 2018, 38, 864-875.	3.8	22
29	Treatment with oleic acid reduces IgE binding to peanut and cashew allergens. <i>Food Chemistry</i> , 2015, 180, 295-300.	8.2	20
30	Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. <i>Journal of Clinical Immunology</i> , 2017, 37, 190-196.	3.8	20
31	RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1107-1119.	3.0	18
32	Antibody deficiency. <i>Pediatric Infectious Disease Journal</i> , 1990, 9, 424-433.	2.0	15
33	Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 354-361.	2.2	15
34	Reaching for best practices in food oral immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 129-130.e3.	1.0	14
35	Identification and Characterization of Anaerobic Modifications on Arginine-111 Residue in Heated Cashew Nuts. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 411-420.	5.2	13
36	Microbiological, Physicochemical, and Immunological Analysis of a Commercial Cashew Nut-Based Yogurt. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8267.	4.1	13

#	ARTICLE	IF	CITATIONS
37	Hizentra for the treatment of primary immunodeficiency. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1293-1307.	3.0	12
38	Chronic Sinusitis as a Manifestation of Primary Immunodeficiency in Adults. <i>American Journal of Rhinology & Allergy</i> , 1994, 8, 29-36.	2.2	11
39	Safety of L-proline as a stabilizer for immunoglobulin products. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 169-178.	3.0	11
40	The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1076-1081.e3.	3.8	10
41	Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex [®] 10% Versus Gammaplex [®] 5% in Subjects with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2017, 37, 301-310.	3.8	10
42	Oral Immunotherapy-Related Awareness, Attitudes, and Experiences Among a Nationally Representative Sample of Food Allergy Patients/Caregivers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4087-4094.e3.	3.8	10
43	A new intravenous immunoglobulin (BIVIGAM [®]) for primary humoral immunodeficiency. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 325-337.	3.0	8
44	Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM [®] and ASCENIV [®] . <i>Immunotherapy</i> , 2019, 11, 1423-1433.	2.0	7
45	Validation of inducible basophil biomarkers: Time, temperature and transportation. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 632-644.	1.5	7
46	Exploiting nut cross-reactivity to facilitate real-world treatment of tree nut allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 149-151.	1.0	7
47	Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials. <i>Journal of Clinical Immunology</i> , 2017, 37, 517-518.	3.8	6
48	Primary structure of the variable regions of two canine immunoglobulin heavy chains. <i>Biochemistry</i> , 1977, 16, 3160-3168.	2.5	5
49	Gammaplex [®] 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura. <i>Immunotherapy</i> , 2017, 9, 1071-1088.	2.0	5
50	Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy. <i>Journal of Clinical Immunology</i> , 2017, 37, 180-186.	3.8	5
51	Unconventional therapies for neonatal sepsis. <i>Pediatric Infectious Disease Journal</i> , 1983, 2, 421-423.	2.0	4
52	Food Oral Immunotherapy (FOIT) Failures: Who and Why. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB134.	2.9	4
53	Measurement of exhaled nitric oxide in young children. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 343-345.	1.0	4
54	20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 93-94.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS). Journal of Allergy and Clinical Immunology, 2017, 139, AB134.	2.9	3
56	Balancing the risks and burdens of food allergen avoidance. Annals of Allergy, Asthma and Immunology, 2018, 120, 229-230.	1.0	3
57	Eosinophilic Esophagitis Like Oral Immunotherapy Related Syndrome (ELORS). Journal of Allergy and Clinical Immunology, 2018, 141, AB258.	2.9	3
58	The real world is not standardized. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2098-2099.	3.8	3
59	Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. Frontiers in Immunology, 2021, 12, 707463.	4.8	3
60	Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency. LymphoSign Journal, 2015, 2, 21-29.	0.2	3
61	Immunoglobulin replacement therapy stewardship in modern times. Annals of Allergy, Asthma and Immunology, 2022, 129, 546-547.	1.0	3
62	Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs). Journal of Allergy and Clinical Immunology, 2014, 133, AB180.	2.9	2
63	Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI). Journal of Allergy and Clinical Immunology, 2015, 135, AB96.	2.9	2
64	Sir., Aids, 1990, 4, 468.	2.2	1
65	Long-Term Efficacy and Tolerability of 20% Scig in the Treatment of Patients with Primary Immunodeficiency Disease. Journal of Allergy and Clinical Immunology, 2013, 131, AB157.	2.9	1
66	Retrospective Analysis Of The Clinical Utility Of Biweekly Dosing With High-Concentration Subcutaneous Immunoglobulin In 10 Patients With Primary Immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 133, AB184.	2.9	1
67	Single Practice Five-Year Experience Treating Food Allergy With Oral Immunotherapy: Efficacy and Epinephrine Treated Reactions. Journal of Allergy and Clinical Immunology, 2014, 133, AB104.	2.9	1
68	Pharmacokinetics of RI-002, an Investigational Igiv Preparation. Journal of Allergy and Clinical Immunology, 2015, 135, AB89.	2.9	1
69	Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies. Journal of Allergy and Clinical Immunology, 2016, 137, AB220.	2.9	1
70	Changing The Outcomes Of Peanut Oral Immunotherapy (POIT). Journal of Allergy and Clinical Immunology, 2019, 143, AB275.	2.9	1
71	Immunology for the Practicing Physician. Pediatric Infectious Disease Journal, 1984, 3, 285.	2.0	0
72	Characterization of the Effects of Proteolysis and Reduction On Cashew Allergens. Journal of Allergy and Clinical Immunology, 2013, 131, AB21.	2.9	0

#	ARTICLE	IF	CITATIONS
73	Single Practice Five Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Effect On Antigen Specific IgE (asIgE). Journal of Allergy and Clinical Immunology, 2014, 133, AB105.	2.9	0
74	Characterizing The Effect Of Sodium Sulfite On Cashew Allergens. Journal of Allergy and Clinical Immunology, 2014, 133, AB115.	2.9	0
75	Effect Of Oleic Acid On The Allergenic Properties Of Peanut and Cashew Allergens. Journal of Allergy and Clinical Immunology, 2014, 133, AB111.	2.9	0
76	Single Practice, Five-Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Successes and Failures. Journal of Allergy and Clinical Immunology, 2014, 133, AB105.	2.9	0
77	Tolerance to Allergenic Foods Following Food Oral Immunotherapy (FOIT). Journal of Allergy and Clinical Immunology, 2015, 135, AB28.	2.9	0
78	Single Practice Six-Year Experience Treating Food Allergy with Oral Immunotherapy. Journal of Allergy and Clinical Immunology, 2015, 135, AB27.	2.9	0
79	Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time. Journal of Allergy and Clinical Immunology, 2016, 137, AB219.	2.9	0
80	Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies. Journal of Allergy and Clinical Immunology, 2017, 139, AB18.	2.9	0
81	Sustained Unresponsiveness Following Food Oral Immunotherapy (FOIT). Journal of Allergy and Clinical Immunology, 2017, 139, AB132.	2.9	0
82	Case Studies. Journal of Clinical Immunology, 2017, 37, 188-189.	3.8	0
83	Nut Oral Immunotherapy (NOIT) for Allergy to One Nut Desensitizes to the Cross Reactive Nut. Journal of Allergy and Clinical Immunology, 2018, 141, AB241.	2.9	0
84	Nut Oral Immunotherapy (NOIT) Using Two or More Nuts Successfully Desensitizes Most Patients. Journal of Allergy and Clinical Immunology, 2018, 141, AB258.	2.9	0
85	Fractional Exhaled Nitric Oxide (FeNO) Measurements with the NIOX VERO Â® in Children 4 to 6 Years Old using the 6 and 10 Second Exhalation Modes. Journal of Allergy and Clinical Immunology, 2018, 141, AB104.	2.9	0
86	Captaining the PIDD ship. Annals of Allergy, Asthma and Immunology, 2019, 123, 419.	1.0	0
87	Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study. Journal of Allergy and Clinical Immunology, 2019, 143, AB117.	2.9	0
88	Interim Safety Data in a Prospective, Open-label, Multi-center Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Plasmacap Ig in Patients with Primary Immunodeficiency Diseases (Pidd). Journal of Allergy and Clinical Immunology, 2019, 143, AB117.	2.9	0
89	Common variable immunodeficiency and respiratory complications: take-home messages for the clinician. Annals of Allergy, Asthma and Immunology, 2020, 124, 414-415.	1.0	0
90	Immunoglobulin replacement. , 2020, , 1143-1156.		0

#	ARTICLE	IF	CITATIONS
91	Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy, 2021, , .	2.0	0